WHO ICTRP trial
Camrelizumab and apatinib combined local treatment of liver cancer real world…
ChiCTR2100041931 · Chinese Clinical Trial Registry (ChiCTR) · Recruiting
Key facts
| Trial ID | ChiCTR2100041931 |
|---|---|
| Public title | Camrelizumab and apatinib combined local treatment of liver cancer real world big data study |
| Scientific title | Camrelizumab and apatinib combined local treatment of liver cancer real world big data study |
| Primary sponsor | Henan Cancer Hospital |
| Registry | Chinese Clinical Trial Registry (ChiCTR) |
| Recruitment status | Recruiting |
| Study type | Observational study |
| Phase | 4 |
| Countries | China |
| Conditions | Liver Cancer |
| Interventions | case series:Nil |
| Registration date | Jan 10, 2021 |
| Target size | case series:512 |
| Registry page | chictr.org.cn |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: